- Germany
- /
- Medical Equipment
- /
- XTRA:SHL
Siemens Healthineers' (ETR:SHL) Upcoming Dividend Will Be Larger Than Last Year's
Siemens Healthineers AG (ETR:SHL) will increase its dividend from last year's comparable payment on the 20th of February to €0.95. This takes the annual payment to 2.0% of the current stock price, which is about average for the industry.
See our latest analysis for Siemens Healthineers
Siemens Healthineers' Dividend Is Well Covered By Earnings
Unless the payments are sustainable, the dividend yield doesn't mean too much. Prior to this announcement, Siemens Healthineers' dividend was comfortably covered by both cash flow and earnings. This indicates that a lot of the earnings are being reinvested into the business, with the aim of fueling growth.
Looking forward, earnings per share is forecast to rise by 36.8% over the next year. If the dividend continues along recent trends, we estimate the payout ratio will be 40%, which is in the range that makes us comfortable with the sustainability of the dividend.
Siemens Healthineers Doesn't Have A Long Payment History
The dividend has been pretty stable looking back, but the company hasn't been paying one for very long. This makes it tough to judge how it would fare through a full economic cycle. The dividend has gone from an annual total of €0.70 in 2019 to the most recent total annual payment of €0.95. This implies that the company grew its distributions at a yearly rate of about 7.9% over that duration. Siemens Healthineers has a nice track record of dividend growth but we would wait until we see a longer track record before getting too confident.
We Could See Siemens Healthineers' Dividend Growing
The company's investors will be pleased to have been receiving dividend income for some time. Siemens Healthineers has seen EPS rising for the last five years, at 5.7% per annum. Shareholders are getting plenty of the earnings returned to them, which combined with strong growth makes this quite appealing.
In Summary
Overall, this is a reasonable dividend, and it being raised is an added bonus. The dividend has been at reasonable levels historically, but that hasn't translated into a consistent payment. Taking all of this into consideration, the dividend looks viable moving forward, but investors should be mindful that the company has pushed the boundaries of sustainability in the past and may do so again.
Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. However, there are other things to consider for investors when analysing stock performance. Case in point: We've spotted 2 warning signs for Siemens Healthineers (of which 1 is concerning!) you should know about. Is Siemens Healthineers not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:SHL
Siemens Healthineers
Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.
Undervalued with solid track record.